The Ministry of Health of Uruguay issued again the Good Manufacturing Practices (GMP) certificate for our injectables plant, after the audit carried out during the month of September.

Working in accordance with World Health Organization standards for drug production has been Libra’s policy since the inception of activities. We have periodically renewed this increasingly demanding certification, thanks to the quality culture of our collaborators and the permanent investment in improvements in structure, technology, and training.

Today, we are the only GMP certified manufacturer of injectable antibiotics in Uruguay.

Thus, we renew our commitment to the system of continuous improvement that ensures an increasingly high-quality standard, and that allows us to affirm that our medicines are reliable, safe and effective.

In order to prevent environmental pollution through the control of wastewater, with the advice of a specialized company, an effluent treatment system was designed and put into operation.

The purpose is to neutralize the antibiotic activity of the wastewater from the washing of the elements used in the manufacture of injectable drugs in our plant. The treatment carried out achieves the chemical neutrality of the effluents prior to their disposal into the sewage network.

Ecotoxicity studies are carried out regularly that allow the system parameters to be adjusted.

LAMICAVIR

Abacavir 600 mg + Lamivudine 300 mg
Coated tablets.

Single-tablet, fixed-dose formulation of two nucleoside-analog reverse transcriptase inhibitors.

Antiretroviral drug prequalified by the World Health Organization.

Recombinant Human Growth Factor.

After a new investment in building expansion and incorporation of technology, our manufacturing plant again obtained the GMP certificate. A manufacturing of high complexity that we carry out according to international norms and standards, becoming a strategic ally for the country and the health system.